Patents Assigned to Regenex LLC
  • TREATMENT METHOD FOR GRAFT-VERSUS-HOST DISEASE
    Publication number: 20220072040
    Abstract: Disclosed is a method for treating or preventing GvHD in a transplant patient by administering to the patient autologous, ex vivo-modified and expanded CD4+CD25+Foxp3+CD127low T reg cells.
    Type: Application
    Filed: November 11, 2019
    Publication date: March 10, 2022
    Applicant: REGENEX LLC
    Inventor: Svetlana N. BYKOVSKAIA
  • Treatment method for relapsing-remitting multiple sclerosis
    Patent number: 9192628
    Abstract: Disclosed is a method for treating relapsing-remitting multiple sclerosis in a patient by administering to the patient autologous, ex vivo-expanded CD4+CD25+Foxp3+CD127low T reg cells when the patient is in remission. Also disclosed is a method of inhibiting the activity of autoimmune, autologous cytotoxic T and B cells in a patient suffering from relapsing-remitting multiple sclerosis, comprising administering a therapeutically effective amount of autologous CD4+CD25+Foxp3+CD127low T reg cells to the patient.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: November 24, 2015
    Assignee: REGENEX LLC
    Inventors: Svetlana Nunevna Bykovskaia, Daria Dmitrievna Eliseeva, Igor Alekseevich Zavalishin
  • TREATMENT METHOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Publication number: 20140170176
    Abstract: Disclosed is a method for treating relapsing-remitting multiple sclerosis in a patient by administering to the patient autologous, ex vivo-expanded CD4+CD25+Foxp3+CD127low T reg cells when the patient is in remission. Also disclosed is a method of inhibiting the activity of autoimmune, autologous cytotoxic T and B cells in a patient suffering from relapsing-remitting multiple sclerosis, comprising administering a therapeutically effective amount of autologous CD4+CD25+Foxp3+CD127low T reg cells to the patient.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 19, 2014
    Applicant: REGENEX LLC
    Inventors: Svetlana Nunevna BYKOVSKAIA, Daria Dmitrievna ELISEEVA, Igor Alekseevich ZAVALISHIN
  • Treatment method for relapsing-remitting multiple sclerosis
    Patent number: 8697060
    Abstract: Disclosed is a method for treating relapsing-remitting multiple sclerosis in a patient by administering to the patient autologous, ex vivo-expanded CD4+CD25+Foxp3+CD127low T reg cells when the patient is in remission. Also disclosed is a method of inhibiting the activity of autoimmune, autologous cytotoxic T and B cells in a patient suffering from relapsing-remitting multiple sclerosis, comprising administering a therapeutically effective amount of autologous CD4+CD25+Foxp3+CD127low T reg cells to the patient.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: April 15, 2014
    Assignee: Regenex LLC
    Inventors: Svetlana Nunevna Bykovskaia, Daria Dmitrievna Eliseeva, Igor Alekseevich Zavalishin
  • TREATMENT METHOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Publication number: 20140004133
    Abstract: Disclosed is a method for treating relapsing-remitting multiple sclerosis in a patient by administering to the patient autologous, ex vivo-expanded CD4+CD25+Foxp3+CD127lowT reg cells when the patient is in remission. Also disclosed is a method of inhibiting the activity of autoimmune, autologous cytotoxic T and B cells in a patient suffering from relapsing-remitting multiple sclerosis, comprising administering a therapeutically effective amount of autologous CD4+CD25?Foxp3+CD127lowT reg cells to the patient.
    Type: Application
    Filed: February 15, 2013
    Publication date: January 2, 2014
    Applicant: Regenex LLC
    Inventors: Svetlana Nunevna BYKOVSKAIA, Daria Dmitrievna ELISEEVA, Igor Alekseevich ZAVALISHIN